Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biodesix Inc (BDSX)

Biodesix Inc (BDSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,060
  • Shares Outstanding, K 7,956
  • Annual Sales, $ 71,320 K
  • Annual Income, $ -42,930 K
  • EBIT $ -32 M
  • EBITDA $ -24 M
  • 60-Month Beta 0.62
  • Price/Sales 0.95
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 103.04%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,262.70% on 07/14/25
  • IV Low 0.00% on 12/04/25
  • Expected Move (DTE 40) 0.09 (1.05%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 13
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 3,116
  • Open Int (30-Day) 3,120
  • Expected Range 8.04 to 8.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.05
  • Number of Estimates 1
  • High Estimate -1.05
  • Low Estimate -1.05
  • Prior Year -1.20
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.40 +19.92%
on 11/20/25
8.69 -11.68%
on 12/05/25
-0.93 (-10.76%)
since 11/05/25
3-Month
5.74 +33.71%
on 09/17/25
10.60 -27.59%
on 09/10/25
-1.15 (-13.06%)
since 09/05/25
52-Week
3.44 +123.37%
on 05/15/25
32.20 -76.16%
on 12/20/24
-18.52 (-70.71%)
since 12/05/24

Most Recent Stories

More News
Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Clinical utility data for Nodify Lung ® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for...

BDSX : 7.68 (-10.13%)
Biodesix Announces Third Quarter 2025 Results and Highlights

Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86...

BDSX : 7.68 (-10.13%)
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting

LOUISVILLE, Colo., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces its Corporate and Scientific presentations, and exhibitor presence...

BDSX : 7.68 (-10.13%)
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays

LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which...

BDSX : 7.68 (-10.13%)
Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025

LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter...

BDSX : 7.68 (-10.13%)
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting

LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST...

BDSX : 7.68 (-10.13%)
Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit

Biodesix partners with three leading Lung Health organizations to bring education and advocacy to healthcare professionals and patients LOUISVILLE, Colo., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biodesix,...

BDSX : 7.68 (-10.13%)
Biodesix Regains Nasdaq Compliance with Bid Price

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

BDSX : 7.68 (-10.13%)
Biodesix Announces One-for-Twenty Reverse Stock Split

LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse...

BDSX : 7.68 (-10.13%)
Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference

LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person...

BDSX : 7.68 (-10.13%)

Business Summary

Biodesix Inc. is a data-driven diagnostic solutions company. It offers blood-based tests across the lung cancer continuum of care. The company also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes...

See More

Key Turning Points

3rd Resistance Point 9.44
2nd Resistance Point 9.06
1st Resistance Point 8.37
Last Price 7.68
1st Support Level 7.30
2nd Support Level 6.93
3rd Support Level 6.23

See More

52-Week High 32.20
Fibonacci 61.8% 21.21
Fibonacci 50% 17.82
Fibonacci 38.2% 14.42
Last Price 7.68
52-Week Low 3.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar